Jacques Corriveau, CEO of Codetta Bio, outlined a unified multi-omics platform designed to deliver simultaneous, absolute quantification of DNA, RNA, and protein biomarkers from a single sample—addressing a critical bottleneck in translational research and clinical development.
Traditional multi-omic approaches rely on fragmented technologies—sequencing or PCR for nucleic acids and immunoassays for proteins—creating operational inefficiencies and complex data integration challenges. Codetta Bio’s strategy centres on consolidating these workflows into a single, PCR-based system, streamlining data generation while improving consistency and scalability.
The platform integrates paramagnetic bead-based capture with high-throughput PCR, converting protein and nucleic acid signals into a unified readout. This enables the generation of coherent, multi-layered datasets without cross-platform normalisation—an important step toward reproducible, clinically actionable biomarker signatures.
Strategically, this convergence supports the development of multi-omic panels for patient stratification and companion diagnostics, offering biotech companies a more efficient path to clinical validation and regulatory approval. By enabling selection of the most informative biomarkers across modalities, the platform enhances predictive power in clinical trials and supports more targeted therapeutic development.
Beyond drug discovery, the technology aligns with broader industry shifts toward liquid biopsy, longitudinal monitoring, and decentralised testing, particularly as advances in spatial biology increase demand for scalable, blood-based assays. Its potential application in areas such as cytokine profiling highlights relevance in both acute care and chronic disease management.
Corriveau emphasised that future adoption of multi-omics will depend on standardised, deployable platforms that reduce complexity while maintaining analytical rigour. In this context, Codetta Bio positions itself as an enabler of next-generation precision medicine—bridging discovery and clinical implementation through integrated, scalable multi-omic solutions.